Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis

Neurology

Volumn 78, Issue 18, 2012, Pages 1383-1389

  Rigotti, D J ^a   Inglese, M ^b   Kirov, I I ^a   Gorynski, E ^a   Perry, N N ^a   Babb, J S ^a   Herbert, J ^a   Grossman, R I ^a   Gonen, O ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N ACETYLASPARTIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSING REMITTING MULTIPLE SCLEORSIS;

EID: 84860784313     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318253d609     Document Type: Article

References (34)

1. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006;129:606-616. (Pubitemid 43278223)
2. Calabresi P. Multiple sclerosis and demyelinating conditions of the central nervous system. In: Goldman L, Ausiello D, eds. Cecil Medicine, 23rd ed. Philadelphia: Saunders Elsevier; 2007.
3. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359:1221-1231. (Pubitemid 34304266)
4. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol Clin 2005;23:17-38, v. (Pubitemid 40126913)
5. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: What have we learnt from animal models. Exp Neurol 2010;225:2-8.
6. Mountford CE, Stanwell P, Lin A, Ramadan S, Ross B. Neurospectroscopy: The past, present and future. Chem Rev 2010;110:3060-3086.
7. Schuff N, Meyerhoff DJ, Mueller S, et al. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol 576:241-262, 2006; discussion 361-243.
8. Rigotti DJ, Inglese M, Gonen O. Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 2007;28:1843-1849. (Pubitemid 350176510)
9. Tiberio M, Chard DT, Altmann DR, et al. Metabolite changes in early relapsing-remitting multiple sclerosis: A two year follow-up study. J Neurol 2006;253:224-230. (Pubitemid 43255895)
10. Sajja BR, Narayana PA, Wolinsky JS, Ahn CW. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: Multicenter study. Mult Scler 2008;14: 73-80. (Pubitemid 351541399)
11. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrastenhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43:56-71. (Pubitemid 28124649)
12. De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 2002;59:1565-1571.
13. Benedetti B, Rigotti DJ, Liu S, Filippi M, Grossman RI, Gonen O. Reproducibility of the whole-brain N-acetylaspartate level across institutions, MR scanners, and field strengths. AJNR Am J Neuroradiol 2007;28: 72-75. (Pubitemid 46147537)
14. Rigotti DJ, Kirov, II, Djavadi B, Perry N, Babb JS, Gonen O. Longitudinal whole-brain N-acetylaspartate concentration in healthy adults. AJNR Am J Neuroradiol 2011;32: 1011-1015.
15. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey: National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
16. Hu J, Javaid T, Arias-Mendoza F, Liu Z, McNamara R, Brown TR. A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy. J Magn Reson B 1995;108:213-219.
17. Mikheev A, Nevsky G, Govindan S, Grossman R, Rusinek H. Fully automatic segmentation of the brain from T1- weighted MRI using Bridge Burner algorithm. J Magn Reson Imaging 2008;27:1235-1241. (Pubitemid 351770672)
18. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: Quantitation with nonecho proton NMR spectroscopy. Magn Reson Med 1998; 40:684-689. (Pubitemid 28493644)
19. Baslow MH. N-acetylaspartate in the vertebrate brain: Metabolism and function. Neurochem Res 2003;28:941-953. (Pubitemid 36438413)
20. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. N-acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 2007;81: 89-131. (Pubitemid 46282272)
21. Behar KL, Rothman DL, Spencer DD, Petroff OA. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magn Reson Med 1994;32: 294-302. (Pubitemid 24274907)
22. Diggle P, Heagerty P, Liang K-Y, Zeger S. Analysis of Longitudinal Data, 2nd ed. New York: Oxford University Press; 2002.
23. Rigotti DJ, Inglese M, Babb JS, et al. Serial whole-brain N-acetylaspartate concentration in healthy young adults. AJNR Am J Neuroradiol 2007;28:1650-1651. (Pubitemid 47598133)
24. Ge Y, Gonen O, Inglese M, Babb JS, Markowitz CE, Grossman RI. Neuronal cell injury precedes brain atrophy in multiple sclerosis. Neurology 2004;62:624-627. (Pubitemid 38252807)
25. Anderson VM, Bartlett JW, Fox NC, Fisniku L, Miller DH. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. J Neurol 2007;254:1588-1594. (Pubitemid 350159908)
26. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256-266.
27. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-2092. (Pubitemid 351842581)
28. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, doubleblind, placebo-controlled phase IIb study. Lancet 2008; 372:1463-1472.
29. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
30. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136-144.
31. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon β-1b. J Neurol 2001;248:979-986. (Pubitemid 36124725)
32. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005; 11:646-651. (Pubitemid 41685134)
33. Costelloe L, Thompson A, Walsh C, Tubridy N, Hutchinson M. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease. J Neurol Neurosurg Psychiatry 2008;79:1245-1248.
34. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology 2006;66:1384-1389. (Pubitemid 43739648)